Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Formula Animal Pharmaceuticals is a Chinese veterinary pharmaceutical manufacturer focused on animal health active pharmaceutical ingredients and related formulations. The company develops, produces, and sells chemical synthetic APIs and water-soluble APIs for veterinary use, with products including florfenicol, ampicillin sodium, amoxicillin sodium, ceftiofur sodium, colistin sulfate, trimethoprim, sulfamethoxazole sodium, doxycycline hydrochloride, and diclazuril-related products. It operates GMP-inspected API synthesis, powder, and premix facilities in Jinan, Shandong, and also offers contract processing/manufacturing support. The business appears commercially oriented rather than a clinical-stage biotech, with emphasis on veterinary raw materials, quality control, and manufacturing capability. The company has also been described as a high-tech and specialized SME in China and has collaborated with local academic institutions on joint R&D.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Formula Animal Pharmaceuticals.